Scolaris Content Display Scolaris Content Display

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 1 PEF ‐ end.
Figures and Tables -
Analysis 1.1

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 1 PEF ‐ end.

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 2 PEF ‐ baseline.
Figures and Tables -
Analysis 1.2

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 2 PEF ‐ baseline.

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 3 PEF ‐ change.
Figures and Tables -
Analysis 1.3

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 3 PEF ‐ change.

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 4 FEV1.
Figures and Tables -
Analysis 1.4

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 4 FEV1.

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 5 Asthma symptom scores.
Figures and Tables -
Analysis 1.5

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 5 Asthma symptom scores.

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 6 Asthma medication usage.
Figures and Tables -
Analysis 1.6

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 6 Asthma medication usage.

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 7 Bronchial hyperresponsiveness (logged).
Figures and Tables -
Analysis 1.7

Comparison 1 n‐3 fatty acid supplementation versus placebo (parallel studies), Outcome 7 Bronchial hyperresponsiveness (logged).

Comparison 2 n‐3 supplementation versus placebo (cross‐over studies), Outcome 1 PEF ‐ end.
Figures and Tables -
Analysis 2.1

Comparison 2 n‐3 supplementation versus placebo (cross‐over studies), Outcome 1 PEF ‐ end.

Comparison 2 n‐3 supplementation versus placebo (cross‐over studies), Outcome 3 Asthma symptom scores.
Figures and Tables -
Analysis 2.3

Comparison 2 n‐3 supplementation versus placebo (cross‐over studies), Outcome 3 Asthma symptom scores.

Comparison 2 n‐3 supplementation versus placebo (cross‐over studies), Outcome 4 Symptomatic deterioration.
Figures and Tables -
Analysis 2.4

Comparison 2 n‐3 supplementation versus placebo (cross‐over studies), Outcome 4 Symptomatic deterioration.

Comparison 3 adults versus children ‐ bronchial hyperresponsiveness (logged), Outcome 1 Adults versus Children.
Figures and Tables -
Analysis 3.1

Comparison 3 adults versus children ‐ bronchial hyperresponsiveness (logged), Outcome 1 Adults versus Children.

Comparison 4 adults versus children ‐ Asthma symptom scores, Outcome 1 Adults versus children.
Figures and Tables -
Analysis 4.1

Comparison 4 adults versus children ‐ Asthma symptom scores, Outcome 1 Adults versus children.

Comparison 1. n‐3 fatty acid supplementation versus placebo (parallel studies)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 PEF ‐ end Show forest plot

4

101

Std. Mean Difference (IV, Random, 95% CI)

1.05 [0.02, 2.08]

2 PEF ‐ baseline Show forest plot

4

101

Std. Mean Difference (IV, Random, 95% CI)

0.04 [‐0.48, 0.56]

3 PEF ‐ change Show forest plot

4

101

Std. Mean Difference (IV, Random, 95% CI)

0.51 [‐0.46, 1.47]

4 FEV1 Show forest plot

2

51

Mean Difference (IV, Fixed, 95% CI)

2.08 [‐4.77, 8.93]

5 Asthma symptom scores Show forest plot

5

124

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.09 [‐0.45, 0.27]

6 Asthma medication usage Show forest plot

4

101

Std. Mean Difference (IV, Random, 95% CI)

‐0.84 [‐2.11, 0.44]

7 Bronchial hyperresponsiveness (logged) Show forest plot

5

108

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.14 [‐0.52, 0.24]

Figures and Tables -
Comparison 1. n‐3 fatty acid supplementation versus placebo (parallel studies)
Comparison 2. n‐3 supplementation versus placebo (cross‐over studies)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 PEF ‐ end Show forest plot

2

88

Mean Difference (IV, Fixed, 95% CI)

5.05 [‐34.29, 44.38]

3 Asthma symptom scores Show forest plot

1

30

Mean Difference (IV, Fixed, 95% CI)

‐0.03 [‐1.75, 1.69]

4 Symptomatic deterioration Show forest plot

1

56

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.28 [0.09, 0.84]

Figures and Tables -
Comparison 2. n‐3 supplementation versus placebo (cross‐over studies)
Comparison 3. adults versus children ‐ bronchial hyperresponsiveness (logged)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Adults versus Children Show forest plot

5

108

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.14 [‐0.52, 0.25]

1.1 Adults

3

46

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.01 [‐0.61, 0.59]

1.2 Children

2

62

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.22 [‐0.72, 0.28]

Figures and Tables -
Comparison 3. adults versus children ‐ bronchial hyperresponsiveness (logged)
Comparison 4. adults versus children ‐ Asthma symptom scores

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Adults versus children Show forest plot

5

130

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.06 [‐0.41, 0.29]

1.1 adults

3

62

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.25 [‐0.76, 0.27]

1.2 Children

2

68

Std. Mean Difference (IV, Fixed, 95% CI)

0.10 [‐0.38, 0.58]

Figures and Tables -
Comparison 4. adults versus children ‐ Asthma symptom scores